Table 5: Comparison between 38 patients with miocardial infarct (MI) and 279 patients without CV events; 14 patients with heart failure and 279 patients without CV events.
MI (n. 38) | Without CV events (n. 279) | p | Heart failure (n. 14) | p | ||
Demographics | F/M | 8/15 | 224/75 | 0.0001 | 11/3 | 1.0 |
Mean age at onset, years (SD) | 55 (11) | 45.7 (15.6) | 0.0009a | 54.5 (13.4) | 0.04a | |
Mean age at baseline, years (SD) | 60 (9.9) | 54.3 (11.9) | 0.01a | 63.3 (9.6) | 0.006a | |
Mean drug exposure duration, years (SD) | 11.3 (7.3) | 18.4 (8.8) | 0.2a | 11.3 (7.3) | 0.48a | |
Mean RA duration at last observation, years (SD) | 13.28 (7.4) | 18.4 (8.8) | 0.6a | 19.4 (7.1) | 0.7a | |
Anti-TNF alfa exposure, n. (%) | 8/38 (21) | 65/214 (30.3) | 0.33 | 8/14 (57) | 0.038 | |
Comorbidities | Arterial hypertension (%) | 7/32 (21.8) | 41/156 (26.2) | 0.66 | 5/11 (45.5) | 0.17 |
Smoking habits (%) | 4/13 (30.7) | 37/156 (23.7) | 0.5 | 1/11 (9) | 0.46 | |
Dyslipidaemia (%) | 13/32 (40.6) | 17/153 (11.1) | < 0.0001 | 5/14 (35.7) | 0.038 | |
Familiar CV disease (%) | 25/32 (78) | 113/279 (40.5) | < 0.0001 | 9/14 (64.3) | 0.09 | |
Diabetes (%) | 8/20 (40) | 7/156 (4.4) | < 0.0001 | 2/11 (18.2) | 0.1 | |
Coronaropathy (%) | 2/16 (12.5) | 4/279 (1.4) | 0.03 | 2/11 (18.2) | 0.018 | |
Mean n. Framingham risk factors at the CV event (SD) | 11.1 (10) | 5.98 (7.2) | 0.0001b | 18.54 (14.5) | < 0.0001b |